Chronic lymphocytic leukemia (CLL): first-line treatment.

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn , Issue , 2005, Pages 285-291

  Hallek, Michael ^a   German CLL Study Group, ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ANEMIA; ARTICLE; CANCER STAGING; CHROMOSOME 11; CHROMOSOME 13; CHROMOSOME 17; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; GENETICS; HUMAN; IMMUNOTHERAPY; METHODOLOGY; PATHOLOGY; PROGNOSIS; QUALITY OF LIFE; THROMBOCYTOPENIA;

ANEMIA; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 17; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM STAGING; PROGNOSIS; QUALITY OF LIFE; THROMBOCYTOPENIA;

EID: 33744802581     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2005.1.285     Document Type: Article

References (0)